Committees

Impact of a no deal Brexit on health and social care inquiry

Inquiry

The Health and Social Care Committee will be holding an evidence session in October on the impact of a no-deal Brexit on health and social care.

Terms of Reference

Ahead of the session, the Committee is inviting written submissions from all interested parties, setting out:

  • What the impact of a no-deal Brexit* is likely to be on their sector of the health and social care system (whether that be patients, suppliers to the health and social care system, providers of NHS or social care services, NHS or social care staff, or others).
  • Specifically, what the risks are to patients and to the health and social care system of leaving the European Union without a withdrawal agreement. The Committee would be particularly pleased to hear from patient representative groups about the extent of the potential risk to patient care of any disruption to the supply from the EU-27 to the UK of medicines, medical devices or substances of human origin.
  • How effectively stakeholders are planning for the possibility of a no-deal Brexit.
  • How effectively they consider the Government is planning for such an outcome.
  • What further planning, or reassurances, are required in order to ensure that the impact of a no-deal Brexit on health and social care would be minimised.

Reports, special reports and government responses

No reports or special reports published.

Correspondence

View all correspondence
Correspondence from the Pharmaceutical Services Negotiating Committee (PSNC) regarding Pharmacies and Brexit, 7 December 2018
Inquiry Impact of a no deal Brexit on health and social care inquiry
Open PDF
Opens in new window
Correspondence
Correspondence from the Secretary of State following session on the impact of a No Deal Brexit on health and social care, 20 November 2018
Inquiry Impact of a no deal Brexit on health and social care inquiry
Open PDF
Opens in new window
Correspondence

Oral evidence transcripts

View all oral evidence transcripts
23 October 2018
Inquiry Impact of a no deal Brexit on health and social care inquiry
Witnesses Saffron Cordery, Deputy Chief Executive, NHS Providers, Professor Tamara Hervey, Jean Monnet Professor of European Union Law, University of Sheffield, Mike Thompson, Chief Executive, Association of British Pharmaceutical Industry, Martin Sawer, Executive Director, Healthcare Distribution Association, Mark Lloyd Davies, Senior Director, Medical Devices and Consumer Medical Technologies, Europe, Middle East and Africa, Johnson & JohnsonRt Hon Matt Hancock MP, Secretary of State for Health and Social Care, Sir Chris Wormald, Permanent Secretary, Department of Health and Social Care
Open PDF
141KB
Open HTML
141KB
Oral Evidence

Written evidence

View all written evidence
Royal Pharmaceutical Society (NDB0081)
Open PDF
22KB
Open HTML
22KB
Nursing and Midwifery Council (NDB0082)
Open PDF
26KB
Open HTML
26KB
HCA Healthcare UK (NDB0001)
Open PDF
22KB
Open HTML
22KB

Other publications

No other publications published.

Contact us

We can't usually help you with an individual problem or a specific complaint.

  • Email: hsccom@parliament.uk
  • Phone: (general enquiries) 020 7219 6182 | 020 7219 3138 (media enquiries)
  • Address: Health and Social Care Committee, House of Commons, London, SW1A 0AA